On May 3, 2022 VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, reported that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022 (Press release, VBL Therapeutics, MAY 3, 2022, View Source [SID1234613371]). In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 – May 26, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMMUNOLGY2022TM
Date: Sunday, May 8th, 2022
Time: 2:30 p.m. PDT
Session Title: They Come and They Go: A Leukocyte Migration Extravaganza
Poster Title: MOSPD2 regulates the activation state of αLβ2 integrin to control monocyte migration

LifeSci Immunology & Inflammation Symposium
Date: Wednesday, May 11th, 2022
Time: 1:00 p.m. to 1:30 p.m. EDT
Format: Overview of VBL’s VB-601 Program
Registration details for the event can be found here

Biomed Israel 2022 Conference
Date: Thursday, May 12th, 2022
Track: Transformative Precision Cancer Diagnostics and Therapies
Time: 9:30 a.m. to 2:00 p.m. IDT
Format: Corporate Overview
Registration details for the event can be found here

H.C. Wainwright Global Investment Conference
Date: Monday, May 23rd – Thursday, May 26th, 2022
Format: Corporate Overview

Links to VBL’s IMMUNOLGY2022TM poster and to the webcast of the LifeSci Symposium will be available on the Events and Presentations page of the Investors section on the Company’s website at www.vblrx.com.

On May 3, 2022 Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, reported that it is participating in the recently announced public-private Oncode-PACT (Press release, Xilis, MAY 3, 2022, View Source [SID1234613429]). Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Across all cancers there remains tremendous unmet needs for new targeted treatment approaches that address the unique attributes of each patient," said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. "Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. Xilis is proud to be part of Oncode-PACT to help support drug discovery and development and help clinicians make more informed treatment decisions through our European-based office in Netherlands."

Xilis’ proprietary tumorsphere microencapsulation platform evaluates cancer therapies at scale and is designed to enable physicians to make precision oncology treatment decisions, identifying treatments that will led to the best response for each patient.

Alain Kummer, Managing Director Oncode Institute and Chairman of Oncode-PACT, explains: "Oncode-PACT places the patient at the center of the entire drug development chain. In the current situation, the preclinical development process is still insufficiently connected with the clinical practice, and we focus on the patient too late in the drug development process."

Oncode-PACT has the ambition to develop new demonstrably effective cancer drugs faster and more cost-effectively. The medical need is urgent, because cancer remains a leading cause of death worldwide.

On May 3, 2022 Centene Corporation (NYSE: CNC) reported it will present at the Bank of America 2022 Healthcare Conference, to be held Monday, May 9-Friday, May 13, 2022, in Las Vegas (Press release, Centene , MAY 3, 2022, View Source [SID1234613446]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Centene will present on Tuesday, May 10th at 8:40 a.m. Pacific Time (PT). A simultaneous live audio webcast is available at: https://bofa.veracast.com/webcasts/bofa/hc2022/idhB56LV.cfm.

A webcast replay will be available afterwards via the Company’s website at www.centene.com, under the Investors section.

On May 3, 2022 Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol"), reported that it will publish the company’s results for the first quarter of 2022 on Thursday, May 12, 2022 (Press release, Isofol Medical, MAY 3, 2022, View Source [SID1234613352]). On the same day, Isofol invites investors, analysts, and media to an audiocast with a subsequent question and answer session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In conjunction with the publication of the interim report for the first quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on May 12, 2022 at 11:00 a.m. CEST. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.

On May 3, 2022 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on Wednesday, May 11, 2022 at 9:00 a.m. ET (Press release, Aclaris Therapeutics, MAY 3, 2022, View Source [SID1234613380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.